Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Research Strategy
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4 Inhibitor
      • RIPK1 Inhibitor
    • Partnered Programs
      • Grifols
      • Kissei
      • Medison
      • BerGenBio
      • Aclaris Therapeutics
      • Daiichi-Sankyo
      • AstraZeneca
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Apr 07, 2021 7:30am EDT

Rigel Announces Closing of Strategic Collaboration with Lilly

Mar 11, 2021 7:30am EST

Rigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients

Mar 02, 2021 4:01pm EST

Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Feb 23, 2021 7:30am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update

Feb 18, 2021 6:30am EST

Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases

Jan 29, 2021 2:45pm EST

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

Jan 11, 2021 7:30am EST

Rigel Pharmaceuticals Provides Business Update

Jan 07, 2021 7:30am EST

Rigel to Present at the 39th Annual J.P. Morgan Healthcare Conference

Dec 04, 2020 7:30am EST

Rigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition

Nov 23, 2020 7:30am EST

Rigel and Medison Announce Health Canada Approval of TAVALISSE®, an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …31
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2021 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin